Cargando…
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable benefit–risk profile and attributes that encourage a high level of treatment adherence. Daclizumab is a humanized mono...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026217/ https://www.ncbi.nlm.nih.gov/pubmed/27672308 http://dx.doi.org/10.2147/BTT.S89218 |